** Shares of drug developer Fractyl Health GUTS.O rise 6.7% to $1.27 premarket
** Co says early-stage data shows its weight management device Revita helps maintain weight in patients after they discontinued taking weight-loss drugs
** One month post-procedure, seven patients experienced an average weight regain of just 1.2%, compared with the ~3% typically observed at this time period after GLP-1 discontinuation based on prior clinical studies - GUTS
** Co expects to announce additional data from the study during Q3 of this year
** Shares of the company have fallen 42.2% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com ))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.